Strategic Alliance The alliance with Cost Plus Drugs signals growing demand for affordable essential medicines and collaborative development. This creates opportunities to expand joint programs across discovery, scale-up synthesis, cGMP manufacturing, and supply chain resiliency initiatives, with potential for co-development and regulatory alignment.

Cost Plus Partnership Position Alchem as the end-to-end manufacturing and analytical services partner for Cost Plus Drugs’ portfolio of essential medicines. Offer capabilities in custom synthesis scale-up, process development, cGMP manufacturing, QA/QC, stability studies, and regulatory-ready documentation to strengthen supply chain reliability.

International Expansion India market activity shows demand for oncology therapies and global access strategies. Alchem can provide local tech transfer, regulatory support, and compliant cGMP manufacturing to accelerate access, while enabling cross-border supply chain resilience between the US and India.

Analytical Partnerships Expand analytical capabilities to support rapid development and release of essential medicines, including method development, validation, stability studies, and release testing. This can shorten time to market, improve data integrity, and generate recurring testing revenue with key partners.

Mid-size Advantage Leverage Alchem’s nimble mid-sized profile to fill capacity gaps for larger clients during peak demand or regulatory transitions, offering flexible manufacturing, rapid process development, and bespoke organic synthesis expertise with a high-service focus to win repeat business.